TLR4 and hepatitis B virus infection: Research has found that inhibiting the expression of TLR4 in the placenta can significantly reduce the release of downstream factors, reduce inflammatory reactions, and significantly improve adverse outcomes in newborns, which has been found in hepatitis B virus infection, E. coli intrauterine infection and other studies.